Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Unknown 1Recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Non-Small-Cell Lung 33Breast Neoplasms 25Rectal Neoplasms 23Esophageal Neoplasms 22Stomach Neoplasms 19Squamous Cell Carcinoma of Head and Neck 18Glioblastoma 16Pancreatic Neoplasms 14Lung Neoplasms 14Head and Neck Neoplasms 12Colorectal Neoplasms 11Brain Neoplasms 10Sarcoma 9Neoplasms 9Colonic Neoplasms 8Adenocarcinoma Of Esophagus 7Melanoma 6Glioma 6Esophageal Squamous Cell Carcinoma 6Ovarian Neoplasms 5Oropharyngeal Neoplasms 5Hypopharyngeal Neoplasms 5Carcinoma, Ovarian Epithelial 5Adenocarcinoma of Lung 5Prostatic Neoplasms 4Mouth Neoplasms 4Gliosarcoma 4Fallopian Tube Neoplasms 4Central Nervous System Neoplasms 4Carcinoma, Squamous Cell 4

Interventions

Gemcitabine 58Cisplatin 32Oxaliplatin 28Fluorouracil 21lenvatinib 19durvalumab 18Capecitabine 17Leucovorin 15pembrolizumab 10tislelizumab 9apatinib 9Floxuridine 8Specimen Handling 7Panitumumab 7Magnetic Resonance Spectroscopy 7Albumin-Bound Paclitaxel 7sintilimab 6pemigatinib 6Radiotherapy 6Irinotecan 6Drug Therapy 6Biopsy 6tremelimumab 5olaparib 5camrelizumab 5Taxes 5S 1 (combination) 5Nivolumab 5Folfox protocol 5Bevacizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Cholangiocarcinoma × Surgical Procedures, Operative × Clear all
NCT06721286 2024-12-06

Toripalimab Combined With Gemcitabine and Cisplatin (GemCis) as Preoperative Neoadjuvant Therapy for Resectable Intrahepatic Cholangiocarcinoma

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Recruiting
70 enrolled
Gastrointestinal

Cirrhosis, Familial, with Pulmonary Hypertension, Cholangiocarcinoma

NCT05672537 2023-01-05

Durvalumab Combined With GemCis Neoadjuvant Therapy of Resectable Intrahepatic Cholangiocarcinoma With High Recurrence Risk

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Unknown
70 enrolled
Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡